DrugPipeline.net has announced the addition of “US Market Report for Liquid Embolics 2017 - MedCore” research report to their website DrugPipeline.net

Bangalore, India -- (SBWire) -- 12/23/2016 --There will be flat growth in the liquid embolics market over the forecast period. The, "A Randomized trial of Unruptured Brain Arteriovenous malformations" (ARUBA) trial compared interventional and conservative treatment of arteriovenous malformations in the brain. Conservative treatment consisted of a regimen of medication while the intervention arm included embolization. The trial was halted in 2013 due to excessive morbidity associated with the interventional arm.

This outcome slowed growth in terms of unit sales in liquid embolics. Innovation in microcatheters to reduce complications in liquid embolic delivery may slightly increase unit sales. Overall growth in units sold will be flat. The total U.S. liquid embolic market includes TRUFILL n-BCA® from Codman & Shurtleff, Inc and Onyx® from Medtronic. Codman has been on the market for longer and tends to have slightly higher pricing however the ASP will be relatively flat over the projected period.

Spanning over 66 pages "US Market Report for Liquid Embolics 2017 - MedCore" report covers Executive Summary, Competitive Analysis, Research Methodology, Disease Overview, Product Assessment, The report covered companies are - Medtronic, Boston Scientific, St. Jude Medical, Cyberonics, Codman & Shurtleff, Stryker, Integra LifeSciences, InoMed, Mizuho America, RauMedic

For more information Visit at: http://www.drugpipeline.net/idata-research/us-market-report-liquid-embolics-2017-medcore

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.